Author： Szucs Thomas
Publisher： Springer Publishing Company
ISSN： 0920-3206
Source： Cardiovascular Drugs and Therapy, Vol.20, Iss.4, 2006-08, pp. : 239-243
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
The NICE Cost-Effectiveness Threshold: What it is and What that Means
PharmacoEconomics, Vol. 26, Iss. 9, 2008-01 ,pp. :
Access to resources
Recommend
Switch from prescription-only to OTC at what cost?
Inpharma, Vol. 1, Iss. 1306, 2001-01 ,pp. :
Preventing MTCT in HIV: what cost in developing countries?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 376, 2002-01 ,pp. :
Preventing MTCT in HIV: what cost in developing countries?
Inpharma, Vol. 1, Iss. 1352, 2002-01 ,pp. :
What's the real cost of preventing chronic disease in the US?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 572, 2009-01 ,pp. :